Biomarker Trial Targeting Rare Sarcoma

Bristol Myers Squibb (BMY) plans to initiate a Phase 1/2 trial (NCT07549022) in August 2026, evaluating navlimetostat (BMS-986504, formerly MRTX1719) in patients with unresectable malignant peripheral nerve sheath tumors (MPNST). The trial will include patients aged 12 years and older with tumors exhibiting homozygous MTAP deficiency. Complete surgical resection is the primary treatment for MPNST, and doxorubicin-based chemotherapy is used for progressive disease; however, there are no approved targeted therapies specifically for MPNST. This study represents a shift in the treatment paradigm by selecting patients based on both histology and genomic vulnerabilities.

PRMT5-MTA Synthetic Lethality Strategy

Navlimetostat, an investigational oral small molecule drug without a commercial brand name, is an inhibitor of methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5). In the absence of MTAP, MTA accumulates within cells, and the drug selectively binds to the PRMT5-MTA complex, blocking the survival dependency of cancer cells. A key aspect is that it is designed to improve therapeutic efficacy compared to earlier-generation compounds that broadly inhibited PRMT5 in normal tissues. An update from a previous Phase 1/2 trial (NCT05245500) reported an objective response rate (ORR) of 23% and a disease control rate (DCR) of 70% in all evaluable patients with advanced solid tumors, with a median duration of response of 10.5 months, which served as the clinical rationale for expanding into MPNST.

Validating Acquired Asset Value

BMS completed the acquisition of Mirati Therapeutics on January 23, 2024, acquiring navlimetostat and Krazati (adagrasib, a KRAS G12C inhibitor). The transaction consists of $4.8 billion in upfront cash and contingent value rights (CVRs) of up to $1 billion, for a total potential value of $5.8 billion. Navlimetostat received FDA Fast Track designation in the third quarter of 2022 but has not yet entered the FDA, EMA, or PMDA approval or advisory committee review stages. This rare cancer study is a program to demonstrate the value of the large acquisition by proving clinical productivity of the acquired asset, with expansion beyond a single indication into a broader range of cancers and regulatory progress.

Competitive Landscape and Market Potential

Direct competitors include Amgen's (AMGN) AMG 193, Tango Therapeutics' (TNGX) vopimetostat (TNG462), and AstraZeneca's (AZN) AZD3470, all of which are MTA-cooperative PRMT5 inhibitors targeting MTAP-deficient cancers and are in Phase 1/2 development. Current treatment for MPNST primarily involves surgery, radiation, and systemic therapy with doxorubicin or ifosfamide, making efficacy and hematological safety key differentiators for targeted therapies. The global sarcoma therapeutics market is projected to grow from approximately $1.4 billion in 2023 to approximately $2.5 billion in 2030, and MTAP deficiency is associated with over 250,000 cancer cases annually in the United States and Europe. Demonstrating efficacy in rare MPNST could strengthen the same biomarker strategy in larger indications such as non-small cell lung cancer, pancreatic cancer, and mesothelioma.